Indolent relapse after initial aggressive B-cell lymphoma: a single institution experience in the rituximab era
Leuk Lymphoma
.
2024 Oct 18:1-4.
doi: 10.1080/10428194.2024.2416563.
Online ahead of print.
Authors
Daniel Fasser
1
2
,
Katharine Lewis
1
,
Connull Leslie
3
,
Gavin Cull
1
,
Dejan Radeski
1
,
Bradley Augustson
1
,
Rebecca Howman
1
,
David Joske
1
,
Julie Crawford
1
,
Carolyn Grove
1
,
Chan Y Cheah
1
2
Affiliations
1
Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, Australia.
2
The University of Western Australia Medical School, Perth, Australia.
3
Department of Anatomical Pathology, PathWest Laboratory Medicine, Nedlands, Australia.
PMID:
39421976
DOI:
10.1080/10428194.2024.2416563
No abstract available
Keywords:
Downgraded lymphoma; clinical observations; histologic transformation; indolent relapse.